{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:57:11Z","timestamp":1791572231179,"version":"4.3.4"},"reference-count":23,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2017,5,19]],"date-time":"2017-05-19T00:00:00Z","timestamp":1495152000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The glucagon\u2010like peptide\u20101 (GLP\u20101) receptor agonists (RAs) exenatide and lixisenatide reduce cholecystokinin (CCK)\u2010induced gallbladder emptying in healthy subjects. It is unknown if all GLP\u20101 RAs share this effect; therefore, the effect of the GLP\u20101 RA albiglutide on gallbladder function was assessed. In this randomized, double\u2010blind, 2\u2010way crossover study, a single dose of subcutaneous albiglutide 50 mg or placebo was administered to 17 healthy subjects, and CCK\u2010induced gallbladder contractility was measured by ultrasonography. CCK (0.003 \u03bcg\/kg) was infused intravenously over 50 minutes on study day 4 (3 days after dosing, to coincide with albiglutide's expected time to maximum concentration). Gallbladder volume, ejection fraction, and the main pancreatic and common bile\u2010duct diameters were measured before, during, and following CCK infusion. Gallbladder volume was significantly greater in the albiglutide vs placebo groups before, during, and after CCK infusion, and the mean difference from placebo increased numerically during CCK infusion. The area under the volume\u2010effect curve was significantly greater with albiglutide (<jats:italic>P<\/jats:italic> = .029). Starting at the 30\u2010minute CCK infusion time point, the gallbladder ejection fraction was significantly lower with albiglutide than placebo. Changes in pancreatic duct diameter and common bile\u2010duct diameter were not significantly different between albiglutide and placebo. Similar incidences of adverse events were observed between the albiglutide and placebo treatment periods. No new albiglutide safety signals were detected, and no serious adverse events were reported. In conclusion, similar to other GLP\u20101 RAs, albiglutide decreased CCK\u2010induced gallbladder emptying compared with placebo in healthy individuals. Clinical implications of the gallbladder effects are unclear at this time.<\/jats:p>","DOI":"10.1002\/jcph.940","type":"journal-article","created":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T19:48:58Z","timestamp":1495568938000},"page":"1322-1329","source":"Crossref","is-referenced-by-count":23,"title":["Effect of Albiglutide on Cholecystokinin\u2010Induced Gallbladder Emptying in Healthy Individuals: A Randomized Crossover Study"],"prefix":"10.1002","volume":"57","author":[{"given":"Bonnie C.","family":"Shaddinger","sequence":"first","affiliation":[{"name":"GlaxoSmithKline  Collegeville PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm A.","family":"Young","sequence":"additional","affiliation":[{"name":"PAREXEL International  Durham NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Billiard","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline  Collegeville PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Collins","sequence":"additional","affiliation":[{"name":"PAREXEL International  Durham NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azra","family":"Hussaini","sequence":"additional","affiliation":[{"name":"PAREXEL International  Baltimore MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Nino","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline  Collegeville PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,5,19]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"Tanzeum [package insert].Research Triangle Park NC:GlaxoSmithKline LLC;2015."},{"key":"e_1_2_9_3_1","unstructured":"Eperzan [summary of product characteristics].County Cork Ireland:GlaxoSmithKline Trading Services Limited;2014."},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(15)00482-9"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2014.11.2836"},{"key":"e_1_2_9_6_1","unstructured":"GlaxoSmithKline.A single\u2010blind randomized placebo\u2010controlled study in healthy men and women to determine the effect of single subcutaneous injections of GSK716155 on gastric emptying time for solid and liquid components of a meal [protocol summary].http:\/\/www.gsk-clinicalstudyregister.com\/study\/GLP107030#ps. Accessed April 4 2017."},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S4283"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12382"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-015-3795-1"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0024"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-014-3360-3"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12414"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0001"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70214-6"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2855"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12679"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12373"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.regpep.2012.08.005"},{"key":"e_1_2_9_19_1","unstructured":"European Medicines Agency (EMA).Committee for Medicinal Products for Human Use (CHMP). Assessment Report: Lyxumia.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002445\/WC500140449.pdf. Published 2012. Accessed November 23 2016."},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2007.01079.x"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12748"},{"key":"e_1_2_9_22_1","first-page":"241","article-title":"Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients","volume":"8","author":"MacConell L","year":"2015","journal-title":"Diabetes Metab Syndr Obes"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.12.8107"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-1716.2010.02235.x"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.940","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.940","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T05:22:15Z","timestamp":1696396935000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,19]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.1002\/jcph.940"],"URL":"https:\/\/doi.org\/10.1002\/jcph.940","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,19]]}}}